SINDU PHARMACEUTICALS
Table of contents:
| Trademark domain | |
| name | is free? |
|---|---|
| sindu-pharmaceuticals.com |  |
| sindupharmaceuticals.com | |
The "SINDU PHARMACEUTICALS" trademark, serial number 78638080 , was filed on 26th of May 2005 with a mark drawing code of 4000 and its transaction date is 78638080. The attorney assigned is Jeffrey D. Hsi, attorney docket number 52461/63498. Since 31st of December 2009, the document can be found in the L90 law office in the publication and issue section. The employee responsible is RAUEN, JAMES A and the date it was published for opposition on 02/14/2006. The status of this trademark was checked last on 06/08/2009.
The corresponded responsible for this trademark is Jeffrey D. Hsi, located at Edwards Angell Palmer & Dodge LLP, F.D.R. Station, P.O. Box 130.The state or country where the trademark was organized is MA by Indus Pharmaceuticals, Inc.. The legal entity type behing it is a Corporation, located at 27 Jenkins Road, Andover, MA zip 01810.
| GOODS AND/OR SERVICES | |
| International Class - 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. | |
|---|---|
| U.S. Class | 052 - Detergents and Soaps |
| Class Status | 6 - Active |
| Status Date | 06/06/2005 |
| Primary Code | 005 |
| International Class - 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. | |
| U.S. Class | 101 - Advertising and Business |
| Class Status | 6 - Active |
| Status Date | 06/06/2005 |
| Primary Code | 042 |
| Goods codes | |
| D10000 | "Pharmaceuticals" |
| GS0051 | pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections, neoplastic disorders namely, hematologic cancer disorders and solid tumors, autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression, metabolic disorders namely, obesity and atherosclerosis, cardiovascular disorders namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases, renal disorders namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water, central nervous system disorders namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction, inflammatory disorders namely, asthma, gout, inflammatory bowel disease, rheumatoid arthritis, gastrointestinal disorders namely, ulcers, emesis, diarrhea, irritable bowel syndrome, hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation, calcification and bone turnover, dermatological and opthalmological disorders |
| GS0421 | pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections, neoplastic disorders namely, hematologic cancer disorders and solid tumors, autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression, metabolic disorders namely, obesity and atherosclerosis, cardiovascular disorders namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases, renal disorders namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water, central nervous system disorders namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction, inflammatory disorders namely, asthma, gout, inflammatory bowel disease, rheumatoid arthritis, gastrointestinal disorders namely, ulcers, emesis, diarrhea, irritable bowel syndrome, hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation, calcification and bone turnover, dermatological and opthalmological disorders |
| PROSECUTION HISTORY | ||||
| Date | Description | Type | Code | |
|---|---|---|---|---|
| 11/09/2006 | EXTENSION 1 GRANTED | S | EX1G - EXTENSION 1 GRANTED | |
| 11/09/2006 | EXTENSION 1 FILED | S | EXT1 - EXTENSION 1 FILED | |
| 11/09/2006 | TEAS EXTENSION RECEIVED | I - Incoming Correspondence | EEXT - TEAS EXTENSION RECEIVED | |
| 05/09/2006 | NOA MAILED - SOU REQUIRED FROM APPLICANT | O - Outgoing Correspondence | NOAM - NOTICE OF ALLOWANCE-MAILED | |
| 12/20/2005 | APPROVED FOR PUB - PRINCIPAL REGISTER | P | CNSA - APPROVED FOR PUB - PRINCIPAL REGISTER | |
| 12/20/2005 | EXAMINER'S AMENDMENT ENTERED | I - Incoming Correspondence | XAEC - EXAMINER'S AMENDMENT ENTERED | |
| 12/20/2005 | EXAMINERS AMENDMENT E-MAILED | F - First Action | GNEA - EXAMINERS AMENDMENT E-MAILED | |
| 12/20/2005 | EXAMINERS AMENDMENT -WRITTEN | R - Renewal | CNEA - EXAMINERS AMENDMENT -WRITTEN | |
| 06/08/2009 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | O - Outgoing Correspondence | MAB6 - ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | |
| 06/08/2009 | ABANDONMENT - NO USE STATEMENT FILED | S | ABN6 - ABANDONMENT - NO USE STATEMENT FILED | |
| 11/07/2008 | EXTENSION 5 GRANTED | S | EX5G - EXTENSION 5 GRANTED | |
| 11/07/2008 | EXTENSION 5 FILED | S | EXT5 - EXTENSION 5 FILED | |
| 11/07/2008 | TEAS EXTENSION RECEIVED | I - Incoming Correspondence | EEXT - TEAS EXTENSION RECEIVED | |
| 05/09/2008 | EXTENSION 4 GRANTED | S | EX4G - EXTENSION 4 GRANTED | |
| 05/09/2008 | EXTENSION 4 FILED | S | EXT4 - EXTENSION 4 FILED | |
| 05/09/2008 | TEAS EXTENSION RECEIVED | I - Incoming Correspondence | EEXT - TEAS EXTENSION RECEIVED | |
| 11/06/2007 | EXTENSION 3 GRANTED | S | EX3G - EXTENSION 3 GRANTED | |
| 11/06/2007 | EXTENSION 3 FILED | S | EXT3 - EXTENSION 3 FILED | |
| 11/06/2007 | TEAS EXTENSION RECEIVED | I - Incoming Correspondence | EEXT - TEAS EXTENSION RECEIVED | |
| 04/26/2007 | EXTENSION 2 GRANTED | S | EX2G - EXTENSION 2 GRANTED | |
| 04/26/2007 | EXTENSION 2 FILED | S | EXT2 - EXTENSION 2 FILED | |
| 04/26/2007 | TEAS EXTENSION RECEIVED | I - Incoming Correspondence | EEXT - TEAS EXTENSION RECEIVED | |
| 02/14/2006 | PUBLISHED FOR OPPOSITION | A - Allowance for Publication | PUBO - PUBLISHED FOR OPPOSITION | |
| 01/25/2006 | NOTICE OF PUBLICATION | O - Outgoing Correspondence | NPUB - NOTICE OF PUBLICATION | |
| 01/04/2006 | LAW OFFICE PUBLICATION REVIEW COMPLETED | O - Outgoing Correspondence | PREV - LAW OFFICE PUBLICATION REVIEW COMPLETED | |
| 12/30/2005 | ASSIGNED TO LIE | A - Allowance for Publication | ALIE - ASSIGNED TO LIE | |
| 12/19/2005 | ASSIGNED TO EXAMINER | D - Assigned to Examiner | DOCK - ASSIGNED TO EXAMINER | |
| 06/06/2005 | NEW APPLICATION ENTERED IN TRAM | I - Incoming Correspondence | NWAP - NEW APPLICATION ENTERED IN TRAM | |
Information gathered on 12/31/2009. No claim is made regarding the current trademark status. This page is not to be used as legal documentation. Always consult a licensed attorney.
Based on public records. Inadvertent errors are possible.
This web site is not associated with, endorsed by, or sponsored by and has no official or unofficial affiliation with the trademark's owners.
This web site is not associated with, endorsed by, or sponsored by and has no official or unofficial affiliation with the trademark's owners.